ALKS-2680 is under clinical development by Synchronicity Pharma and currently in Phase I for Narcolepsy. According to GlobalData, Phase I drugs for Narcolepsy have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ALKS-2680’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ALKS-2680 is under development for the treatment of narcolepsy. The drug candidate acts by targeting orexin receptor type 2. it is administered through oral route.
It was under development for the treatment of disorders associated with excessive daytime sleepiness.
Synchronicity Pharma overview
Synchronicity Pharma discovers and develops novel therapies for the treatment of metabolic disorders, narcolepsy and diabetes. The company has developed a proprietary platform which is designed to identify and characterize compounds that modulate the activity and function of molecular clocks and discovers drugs which modulate these clocks and clock-controlled systems. Synchronicity Pharma discovery programs include cryptochrome modulator programs and orexin modulator programs. The company conducts cryptochrome modulator programs to develop therapies for cushing’s syndrome and Type 2 diabetes; orexin modulator programs for narcolepsy and disorders associated with the excessive daytime sleepiness. The company works in collaboration with Alkermes plc and Bay City Capital. Synchronicity Pharma is headquartered in San Francisco, California, the US.
For a complete picture of ALKS-2680’s drug-specific PTSR and LoA scores, buy the report here.